RBC maintains Allos at sector perform

Allos Therapeutics, Inc. was maintained at sector perform, speculative risk, and $5 price target by RBC Capital Markets analyst Jason Kantor. The analyst believes there is a low probability that the ongoing phase 3 Enrich trial of lead drug efaproxiral will be stopped early at the second interim analysis in the second half of the year. There is an above average clinical risk as the trial design is based on a small subgroup of a phase 3 trial that missed its primary endpoint. Shares of the Westminster, Colo.-based biopharmaceutical products company were down 8 cents, or 1.93%, at $4.07. (Nasdaq: ALTH)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.